Amarin Corp Plc (AMRN)

[Biobillionair]

Why Vascepa growth is exponential after CV label:
Slide 14

Number needed to treat (NNT): 21 for primary endpoint
? Low NNT combined with affordable price of Vascepa
should support continued broad managed care coverage
? For context, NNTs for other notable, but not competitive with
Vascepa, drugs:
? Atorvastatin (Lipitor®)1
: 45
? Evolocumab (Repatha®)2
: 67
• No head-to-head study with these drugs
• Study periods and study populations differ
~1 fewer MACE per 6 patients treated in total event analysis4
? Result should be helpful in pharmacoeconomic analysis

https://investor.amarincorp.com/static-files/c2473067-dcab-47ea-9968-b908da51c671

Dominate Heath Care Economics aligns payers to labeling.

Current TRX ~70,000...exponential growth from this point leads to TRX > 1,000,000.

Why do banks cap sales at $4bn? Ignorance.

BB